<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04165837</url>
  </required_header>
  <id_info>
    <org_study_id>1ST-102-01</org_study_id>
    <nct_id>NCT04165837</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Pharmacokinetics of Oral FB-101 in Healthy Subjects</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral FB-101 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>1ST Biotherapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>1ST Biotherapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of&#xD;
      oral doses of FB-101 in healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part A&#xD;
&#xD;
        -  To assess the safety and tolerability of single ascending oral doses of FB-101 in&#xD;
           healthy subjects.&#xD;
&#xD;
        -  To assess the pharmacokinetics (PK) of single ascending oral doses of FB-101 in healthy&#xD;
           subjects.&#xD;
&#xD;
        -  To assess the effect of a high-fat meal on the PK of a single oral dose of FB-101 when&#xD;
           administered to healthy subjects.&#xD;
&#xD;
      Part B&#xD;
&#xD;
        -  To assess the safety and tolerability of multiple ascending oral doses FB-101 in healthy&#xD;
           subjects.&#xD;
&#xD;
        -  To assess the PK of multiple ascending oral doses of FB-101 in healthy subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">October 14, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number and severity of treatment emergent adverse events (TEAEs)</measure>
    <time_frame>7 days after the last dose</time_frame>
    <description>To assess the safety and tolerability of single and multiple ascending oral doses of FB-101 in healthy adult subjects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak plasma concentration of FB-101 in plasma</measure>
    <time_frame>72 hours after the last dose</time_frame>
    <description>PK of FB-101</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve of FB-101 in plasma</measure>
    <time_frame>72 hours after the last dose</time_frame>
    <description>PK of FB-101</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak plasma concentration of FB-101 in plasma under fed condition</measure>
    <time_frame>72 hours after the last dose</time_frame>
    <description>Food effect on the PK of FB-101</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve of FB-101 in plasma under fed condition</measure>
    <time_frame>72 hours after the last dose</time_frame>
    <description>Food effect on the PK of FB-101</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FB-101</intervention_name>
    <description>Part A - Single Ascending Dose study Part B - Multiple Ascending Dose study</description>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Part A - Single Ascending Dose matching placebo study Part B - Multiple Ascending Dose matching placebo study</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy, adult, male or female (of non childbearing potential only) 19 55 years of&#xD;
             age, inclusive, at screening.&#xD;
&#xD;
          2. Continuous non smoker who has not used nicotine containing products for at least 3&#xD;
             months prior to (the first) dosing and throughout the study, based on subject self&#xD;
             reporting.&#xD;
&#xD;
          3. Body mass index (BMI) ≥ 18 and ≤ 32.0 kg/m2 at screening.&#xD;
&#xD;
          4. Medically healthy with no clinically significant medical history, physical&#xD;
             examination, neurological examination, ophthalmic examination, laboratory profiles,&#xD;
             vital signs or ECGs, as deemed by the PI or designee.&#xD;
&#xD;
          5. A female subject must be of non childbearing potential and must have undergone one of&#xD;
             the following sterilization procedures at least 6 months prior to (the first) dosing:&#xD;
&#xD;
               -  hysteroscopic sterilization;&#xD;
&#xD;
               -  bilateral tubal ligation or bilateral salpingectomy;&#xD;
&#xD;
               -  hysterectomy;&#xD;
&#xD;
               -  bilateral oophorectomy; or&#xD;
&#xD;
               -  be postmenopausal with amenorrhea for at least 1 year prior to (the first) dosing&#xD;
                  and follicle stimulating hormone (FSH) serum levels consistent with&#xD;
                  postmenopausal status.&#xD;
&#xD;
          6. A non vasectomized, male subject must agree to use a condom with spermicide or abstain&#xD;
             from sexual intercourse during the study until 90 days after (the last) dosing. (No&#xD;
             restrictions are required for a vasectomized male provided his vasectomy has been&#xD;
             performed 4 months or more prior to (the first) dosing of study drug. A male who has&#xD;
             been vasectomized less than 4 months prior to study (first) dosing must follow the&#xD;
             same restrictions as a non vasectomized male).&#xD;
&#xD;
          7. If male, must agree not to donate sperm from the first dosing until 90 days after (the&#xD;
             last) dosing.&#xD;
&#xD;
          8. Able to swallow multiple capsules.&#xD;
&#xD;
          9. Understands the study procedures in the informed consent form (ICF), and be willing&#xD;
             and able to comply with the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Is mentally or legally incapacitated or has significant emotional problems at the&#xD;
             time of the screening visit or expected during the conduct of the study.&#xD;
&#xD;
             2. History or presence of clinically significant medical or psychiatric condition or&#xD;
             disease in the opinion of the PI or designee.&#xD;
&#xD;
             3. History of any illness that, in the opinion of the PI or designee, might confound&#xD;
             the results of the study or poses an additional risk to the subject by their&#xD;
             participation in the study.&#xD;
&#xD;
             4. Is at suicidal risk in the opinion of the PI as per the following criteria:&#xD;
&#xD;
               1. Any suicide attempts within 12 months prior to screening or any suicidal intent,&#xD;
                  including a plan, within 3 months prior to screening.&#xD;
&#xD;
               2. C-SSRS answer of &quot;YES&quot; on suicidal ideation within 3 months prior to screening.&#xD;
                  5. History or presence of alcoholism or drug abuse within the past 2 years prior&#xD;
                  to (the first) dosing.&#xD;
&#xD;
                  6. History or presence of hypersensitivity or idiosyncratic reaction to the study&#xD;
                  drug or related compounds.&#xD;
&#xD;
                  7. History of allergy to lignocaine/fluorescein (LF) or tropicamide (T) (eye&#xD;
                  examination agents).&#xD;
&#xD;
                  8. History of seizures (childhood febrile seizures are excepted). 9. Female&#xD;
                  subjects of childbearing potential. 10. Female subjects with a positive pregnancy&#xD;
                  test or who are lactating. 11. Positive urine drug or alcohol results at&#xD;
                  screening or check in. 12. Positive results at screening for human&#xD;
                  immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C&#xD;
                  virus (HCV).&#xD;
&#xD;
                  13. Supine blood pressure is less than 90/40 mmHg or greater than 140/90 mmHg at&#xD;
                  screening.&#xD;
&#xD;
                  14. Supine heart rate is lower than 40 bpm or higher than 99 bpm at screening.&#xD;
                  15. Estimated creatinine clearance &lt;90 mL/min at screening. 16. Unable to refrain&#xD;
                  from or anticipates the use of any drug including prescription and non&#xD;
                  prescription medications, herbal remedies, or vitamin supplements beginning 14&#xD;
                  days prior to the first dosing and throughout the study. Drugs known to be&#xD;
                  significant inducers of cytochrome P450 (CYP) enzymes and/or P-glycoprotein (P&#xD;
                  gp), including St. John's Wort will be prohibited for 28 days prior to the first&#xD;
                  dosing and throughout the study. After dosing, acetaminophen (up to 2 g per 24&#xD;
                  hours) may be administered at the discretion of the PI or designee. For subjects&#xD;
                  having CSF sampling, topical medication for minor dermatological conditions,&#xD;
                  stool softeners, local anesthetics, and/or intravenous normal saline may be&#xD;
                  permitted as appropriate for lumbar puncture procedure for CSF sample collection&#xD;
                  at the discretion of the PI.&#xD;
&#xD;
                  17. Has been on a diet incompatible with the on study diet, in the opinion of the&#xD;
                  PI or designee, within the 30 days prior to (the first) dosing and throughout the&#xD;
                  study.&#xD;
&#xD;
                  18. Donation of blood or significant blood loss within 56 days prior to (the&#xD;
                  first) dosing.&#xD;
&#xD;
                  19. Plasma donation within 7 days prior to (the first) dosing. 20. Participation&#xD;
                  in another clinical study within 30 days prior to the (first) dosing. The 30 day&#xD;
                  window will be derived from the date of the last blood collection or dosing,&#xD;
                  whichever is later, in the previous study to Day 1 (of Period 1 for the Fed&#xD;
                  Cohort) of the current study.&#xD;
&#xD;
                  21. History or presence of: risk factors for Torsade de Pointes (e.g., heart&#xD;
                  failure, cardiomyopathy, or family history of Long QT Syndrome); sick sinus&#xD;
                  syndrome, second or third degree atrioventricular block, myocardial infarction,&#xD;
                  pulmonary congestion, symptomatic or significant cardiac arrhythmia, prolonged&#xD;
                  QTcF interval, or conduction abnormalities.&#xD;
&#xD;
                  22. Has an abnormal screening ECG indicating a second- or third- degree AV block,&#xD;
                  or one or more of the following: QRS &gt; 120 msec, QTcF &gt; 450 msec for males and &gt;&#xD;
                  460 msec for females, PR interval &gt; 220 msec. Any rhythm other than normal sinus&#xD;
                  rhythm, which is interpreted by the PI or designee to be clinically significant&#xD;
                  at screening or check-in.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jinhwa Lee, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>1ST Biotherapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Minwoo Lee</last_name>
    <phone>+82-31-8023-5332</phone>
    <email>info@1stbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>PAREXEL</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Minwoo Lee</last_name>
      <email>info@1stbio.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 13, 2019</study_first_submitted>
  <study_first_submitted_qc>November 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2019</study_first_posted>
  <last_update_submitted>November 24, 2019</last_update_submitted>
  <last_update_submitted_qc>November 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

